Congratulations to Our Five New Board Members!

We are thrilled to introduce our five newest members of the ASGCT Board of Directors! Starting June 1, these new members will begin their three-year terms. The incoming Vice President will ascend through the presidential succession process before serving as ASGCT President in 2024-25.

Vice President (Term of Office: 2022-2025)

Paula Cannon, PhD
University of Southern California

Dr. Cannon is a distinguished professor of microbiology at the Keck School of Medicine of USC, where she leads a research team that studies viruses, stem cells, and gene therapy. She has a long-standing interest in the development of gene therapy as a clinical approach to treating HIV infection; her recent work in this area is aimed at disrupting the viral co-receptor, CCR5, using zinc finger nucleases (ZFNs).

Secretary (2022-2025)

Isabelle Riviere, PhD
Memorial Sloan Kettering Cancer Center

Dr. Riviere is director of the cell therapy and cell engineering facility at MSKCC, where she investigates novel strategies for cell therapies and immunotherapies to increase or retarget the immune response against tumors and treat hematological disorders.

At-Large Director (2022-2025)

Lindsey George, MD
Children's Hospital of Philadelphia

Dr. George is the director of clinical in vivo gene therapy and an attending physician in the division of hematology at CHOP. Her basic science laboratory studies the molecular basis of coagulation that in diminished or excess functional states leads to disorders of hemostasis and thrombosis, respectively.

At-Large Director (2022-2025)

Aravind Asokan, PhD
Duke University

Dr. Asokan is the director of gene therapy and a professor in surgery, biomedical engineering, and molecular genetics and microbiology. His research lab engineers synthetic molecular and viral tools to enable gene therapy, genome editing, and related therapeutic platforms.

At-Large Director
Membership Council Chair (2022-2025)

Jennifer Wellman, MS
Akouos

Ms. Wellman is chief operating officer at Akouos and has 20 years of experience in AAV vector gene therapy research and development. In her previous role at Spark Therapeutics, of which she is a co-founder, Ms. Wellman led the regulatory and clinical development for several AAV gene therapies, including Luxturna, the first FDA-approved gene therapy for a genetic disease.